Dysregulation of the gain of CICR through ryanodine receptor1 (RyR1): The putative mechanism underlying malignant hyperthermia

Advances in Experimental Medicine and Biology

Volumn 592, Issue , 2007, Pages 287-294

  Ogawa, Yasuo ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PROTEIN CICR; RYANODINE RECEPTOR 1; UNCLASSIFIED DRUG;

BRAIN DYSFUNCTION; CONFERENCE PAPER; HUMAN; MALIGNANT HYPERTHERMIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SARCOPLASMIC RETICULUM; SEQUENCE HOMOLOGY;

EID: 84934437156     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-4-431-38453-3_24     Document Type: Conference Paper

References (35)

1. 2+ release channels and their regulation by endogenous effectors, Ann. Rev. Physiol. 56, 485-508 (1994).
2. 2+ release channels: does diversity in form equal diversity in function? Physiol. Rev. 76, 1027-1071 (1996).
3. C. Franzini-Armstrong, and F. Protasi, Ryanodine receptors of striated muscles: a complex channel capable of multiple interactions, Physiol. Rev. 77, 699-729 (1997).
4. 2+ signaling and muscle disease, Eur. J. Biochem. 267, 5291-5297 (2000).
5. Y. Ogawa, Role of ryanodine receptors, Crit. Rev. Biochem. Mol. Biol. 29, 229-274 (1994).
6. V. Sorrentino, and C. Reggiani, Expression of the ryanodine receptor type 3 in skeletal muscle. A new partner in excitation-contraction coupling? Trends Cardiovasc. Med. 9, 54-61 (1999).
7. M. Endo, Calcium release from the sarcoplasmic reticulum, Physiol. Rev. 57, 71-108 (1977).
8. M. F. Schneider, and W. K. Chandler, Voltage dependent charge movement in skeletal muscle: a possible step in excitation-contraction coupling, Nature 242, 244-246 (1973).
9. T. Murayama, and Y. Ogawa, Roles of two ryanodine receptor isoform coexisting in skeletal muscle, Trends Cardiovasc. Med. 12, 305-311 (2002).
10. 2+ release between α- and β-RyR, J. Biol. Chem. 276, 2953-2960 (2001).
11. T. Murayama, and Y. Ogawa, RyR1 exhibits lower gain of CICR activity than RyR3 in the SR: evidence for selective stabilization of RyR1 channel, Am. J. Physiol. Cell. Physiol. 287, C36-C45 (2004).
12. 2+ channel regulation, J. Biol. Chem. 275, 11618-11625 (2000).
13. 2+ release by interdomain interaction within ryanodine receptors, Front. Biosci. 7, d671-d683 (2002).
14. 2+ release channel and cell regulation defects, Physiol. Rev. 76, 537-592 (1996).
15. M. Denborough, Malignant hyperthermia, Lancet 352(9134), 1131-1136 (1998).
16. K. Jurkat-Rott, T. McCarthy, and F. Lehmann-Horn, Genetic and pathogenesis of malignant hyperthermia, Muscle Nerve 23, 4-17 (2000).
17. 2+ regulating proteins, Curr. Mol. Med. 2, 347-369 (2002).
18. M. Brini, Ryanodine receptor defects in muscle genetic diseases, Biochem. Biophys. Res. Commun. 322, 1245-1255 (2004).
19. N. A. Benkusky, E. F. Farrell, and H. H. Valdivia, Ryanodine receptor channelopathies, Biochem. Biophys. Res. Commun. 322, 1280-1285 (2004).
20. R. T. Dirksen, and G. Avila, Pathophysiology of muscle disorders linked to mutations in the skeletal muscle ryanodine receptor, in: Ryanodine Receptors: Structure, Function and Dysfunction in Clinical Disease, edited by X. H. Wehrens, and A. R. Marks (Springer Science, New York, 2005), pp. 229-242.
21. M. Endo, S. Yagi, T. Ishizuka, K. Horiuti, Y. Koga, and K. Amaha, Changes in the Ca-induced Ca release mechanism in the sarcoplasmic reticulum of the muscle from a patient with malignant hyperthermia, Biomed. Res. 4, 83-92 (1983).
22. 2+ release channels in malignant hyperthermia, Biophys. J. 73, 1913-1924 (1997).
23. 2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease, J. Biol. Chem. 272, 26332-26339 (1997).
24. 2+ dependence of the RyR1, Biophys. J. 81, 2050-2058 (2001).
25. T. Yang, T. A. Ta, I. N. Pessah, and P. D. Allen, Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling, J. Biol. Chem. 278, 25722-25730 (2003).
26. 2+ release activity of mammalian skeletal muscle sarcoplasmic reticulum, Am. J. Physiol. Cell. Physiol. 288, 1222-1230 (2005).
27. T. Yamamoto, and N. Ikemoto, Spectroscopic monitoring of local conformational changes during the intramolecular domain-domain interaction of the ryanodine receptor, Biochemistry 41, 1492-1501 (2002).
28. T. Krause, M. V. Gerbershagen, M. Fiege, R. Weisshorn, and F. Wrappler, Dantrolene: a review of its pharmacology, therapeutic use and new developments, Anesthesia 59, 364-373 (2004).
29. K. Paul-Pletzer, T. Yamamoto, M. B. Bhat, J. Ma, N. Ikemoto, L.S. Jimenez, H. Morimoto, P. G. Williams, and J. Parness, Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor, J. Biol. Chem. 277, 34918-34923 (2002).
30. S. Kobayashi, M. L. Bannister, J. P. Gangopadhyay, T. Hamada, J. Parness, and N. Ikemoto, Dantrolene stabilizes domain interactions within the ryanodine receptor, J. Biol. Chem. 280, 6580-6587 (2005).
31. 2+ release in malignant hyperthermia-susceptible pig skeletal muscle, Am. J. Physiol. Cell. Physiol. 256, C358-C367 (1989).
32. 2+ release by direct and specific action at skeletal muscle ryanodine receptors, J. Biol. Chem. 272, 26965-26971 (1997).
33. T. Murayama, T. Oba, E. Katayama, H. Oyamada, K. Oguchi, M. Kobayashi, K. Otsuka, and Y. Ogawa, Further characterization of type 3 ryanodine receptor (RyR3) purified from rabbit diaphragm, J. Biol. Chem. 274, 17297-17308 (1999).
34. 2+ release channel at 14 Å resolution, J. Mol. Biol. 345, 427-431 (2005).
35. Z. Liu, R. Wang, J. Zhang, S. R. W. Chen, and T. Wagenknecht, Localization of a disease-associated mutation site in the three-dimensional structure of cardiac ryanodine receptor, J. Biol. Chem. 280, 37941-37947.